Pfizer (PFE) Return on Invested Capital (2009 - 2026)

Pfizer (PFE) has reported Return on Invested Capital for 18 consecutive years, with 0.03% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Invested Capital fell 3.0% year-over-year to 0.03%; the TTM figure through Mar 2026 stood at 0.03% (down 3.0% YoY), while the FY2025 annual figure was 0.07%, down 2.0% from the prior year.
• Return on Invested Capital retreated to 0.03% in Q1 2026 per PFE's latest filing, from 0.03% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.04% in Q3 2022 and bottomed at 0.03% in Q1 2026.
• Historically, Return on Invested Capital has averaged 0.0% across 5 years, with a median of 0.0% in 2025.
• Annual changes were most pronounced in 2022 — Return on Invested Capital grew 3 bps — and 2024, when it decreased 4 bps.
• Pfizer's Return on Invested Capital stood at 0.04% in 2022, then sank by 122 bps to 0.01% in 2023, then soared by 117 bps to 0.0% in 2024, then tumbled by 1794 bps to 0.03% in 2025, then fell by 4 bps to 0.03% in 2026.
• Business Quant data shows PFE's Return on Invested Capital at 0.03% in Q1 2026, 0.03% in Q4 2025, and 0.01% in Q3 2025.